A novel synthetic adjuvant enhances dendritic cell function.
The lipid core peptide (LCP) is a novel, synthetic, self-adjuvanted vaccine delivery system that neatly incorporates the adjuvant, carrier and antigenic peptides of a vaccine into a single molecular entity. This system has been previously shown to efficiently deliver vaccines and induce immunity. Because adjuvants target sentinels of the immune response, such as dendritic cells (DCs), that are widely distributed throughout the body to initiate specific immune responses, we investigated the effects of the adjuvant on DCs. Here we show that LCP targets vaccines to DCs and induces their activation.
Phillipps
Karen S M
KS
School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St Lucia, Queensland, Australia.
Wykes
Michelle N
MN
Liu
Xue Q
XQ
Brown
Melissa
M
Blanchfield
Joanne
J
Toth
Istvan
I
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006801:Humans; D018664:Interleukin-12 / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D014162:Transfection; D015854:Up-Regulation; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; C495342:TLR2 protein, human; D051195:Toll-Like Receptor 2; D014612:Vaccines; D018664:Interleukin-12; D010047:Ovalbumin